2026-06-13

BTC open interest -42.8% — OI collapse

ETH open interest -63.5% — OI collapse

SOL open interest -24.2% — OI collapse

ETH open interest -68.8% — OI collapse

SOL open interest -64.0% — OI collapse

BTC open interest -42.8% — OI collapse

SOL DEX volume/liquidity ratio elevated (0.90x) — strong on-chain trading activity

Phase 3 trial terminated early — JOHNSON A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Dise

Phase 3 trial terminated early — JOHNSON An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the

Phase 3 trial terminated early — JOHNSON To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Canc

Phase 3 trial terminated early — ELI Atomoxetine for Children With Acquired Attentional Disorders Following Completio

Phase 3 trial terminated early — ELI Abciximab in Wake-up Stroke

Phase 3 trial terminated early — ELI A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to C

Phase 3 trial terminated early — ELI A Study for Patients With Multiple Sclerosis

Phase 3 trial terminated early — BRISTOL Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With

Phase 3 trial terminated early — BRISTOL A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants

Phase 3 trial terminated early — BRISTOL Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for T

Phase 3 trial terminated early — BIOGEN A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early

Phase 3 trial terminated early — BIOGEN Tecfidera Slow-Titration Study

Phase 3 trial terminated early — AMGEN Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthrit

Phase 3 trial terminated early — INCYTE A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy i

Phase 3 trial terminated early — REGENERON Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gem

Phase 3 trial terminated early — REGENERON Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermati

Phase 3 trial terminated early — REGENERON REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimum

Phase 3 trial terminated early — Medtronic AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibri

Phase 3 trial terminated early — Medtronic OneShot Renal Denervation Registry

Phase 3 trial terminated early — Medtronic Tibial Delayed Healing Pivotal Clinical Trial

Phase 3 trial terminated early — AbbVie MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Tr

Phase 3 trial terminated early — AbbVie Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therap

Phase 3 trial terminated early — ABBOTT Creon in HIV Patients With Steatorrhea

Phase 3 trial terminated early — ABBOTT Niacin Plus Statin to Prevent Vascular Events

Phase 3 trial terminated early — ABBOTT Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery D

Phase 3 trial terminated early — ABBOTT Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients W

Phase 3 trial terminated early — PFIZER Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study

Phase 3 trial terminated early — PFIZER Study Evaluating Bifeprunox in Patients With Schizophrenia.

Phase 3 trial terminated early — PFIZER Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients

Phase 3 trial terminated early — PFIZER Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury

Phase 3 trial terminated early — Merck Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovari

Phase 3 trial terminated early — Merck Raptiva in Palm and Sole Psoriasis

Phase 3 trial terminated early — Merck Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria

Phase 3 trial terminated early — Merck Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Hea

Phase 3 trial terminated early — Merck Cubicin(R) for Complicated Post-surgical Wound Infections

Phase 3 trial terminated early — Merck Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Thera

Phase 3 trial terminated early — Merck Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morb

Phase 3 trial terminated early — Merck A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sita

Phase 3 trial terminated early — Merck Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients

Phase 3 trial terminated early — GILEAD Dose Optimization Study of Idelalisib in Follicular Lymphoma

Phase 3 trial terminated early — GILEAD Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab

Phase 3 trial terminated early — GILEAD Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability

Phase 3 trial terminated early — GILEAD Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inh

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

PDD Holdings Inc. search volume spiked +100 pts — unusual interest

Missed consensus by 29.5% — EPS $-0.55 vs $-0.4246 estimate

Beat consensus by 20.6% — EPS $-0.26 vs $-0.3276 estimate

Beat consensus by 106.0% — EPS $0.03 vs $-0.5042 estimate

Missed consensus by 201.3% — EPS $-0.59 vs $-0.1958 estimate

Beat consensus by 7.4% — EPS $0.43 vs $0.4005 estimate

Beat consensus by 11.6% — EPS $0.41 vs $0.3674 estimate

Beat consensus by 15.5% — EPS $0.42 vs $0.3636 estimate

Beat consensus by 13.5% — EPS $-3.31 vs $-3.825 estimate

Beat consensus by 35.6% — EPS $-2.43 vs $-3.774 estimate

Missed consensus by 20.0% — EPS $-4.53 vs $-3.774 estimate

Beat consensus by 311.8% — EPS $0.21 vs $0.051 estimate

Beat consensus by 72.0% — EPS $-0.01 vs $-0.0357 estimate

Missed consensus by 20.8% — EPS $1.21 vs $1.5278 estimate

Beat consensus by 118.4% — EPS $0.18 vs $0.0824 estimate

Beat consensus by 26.5% — EPS $-0.02 vs $-0.0272 estimate

Beat consensus by 11.8% — EPS $-0.03 vs $-0.034 estimate

Beat consensus by 77.7% — EPS $-0.01 vs $-0.0449 estimate

Beat consensus by 38.1% — EPS $-0.04 vs $-0.0646 estimate

Missed consensus by 23.9% — EPS $-0.22 vs $-0.1775 estimate

Beat consensus by 11.5% — EPS $-0.17 vs $-0.1921 estimate

Missed consensus by 13.5% — EPS $-0.21 vs $-0.1851 estimate

Missed consensus by 144.5% — EPS $-0.49 vs $-0.2004 estimate

Beat consensus by 44.3% — EPS $-0.06 vs $-0.1078 estimate

Beat consensus by 5.5% — EPS $1.16 vs $1.0996 estimate

Beat consensus by 103.3% — EPS $0.55 vs $0.2706 estimate

Beat consensus by 7.8% — EPS $1.76 vs $1.6334 estimate

Missed consensus by 6.2% — EPS $1.53 vs $1.6309 estimate

Beat consensus by 28.8% — EPS $3.1 vs $2.4072 estimate

Missed consensus by 19.3% — EPS $2.37 vs $2.9376 estimate

Missed consensus by 29.4% — EPS $-0.04 vs $-0.0309 estimate

Missed consensus by 21.4% — EPS $-0.05 vs $-0.0412 estimate

Missed consensus by 63.4% — EPS $-3.9 vs $-2.3868 estimate

Missed consensus by 1439.9% — EPS $-15.99 vs $1.1934 estimate

Missed consensus by 126.9% — EPS $-4.93 vs $-2.1726 estimate

Missed consensus by 6707.4% — EPS $-27.08 vs $-0.3978 estimate

Beat consensus by 10.1% — EPS $-2.2 vs $-2.448 estimate

Beat consensus by 12.9% — EPS $-1.6 vs $-1.836 estimate

Missed consensus by 25.3% — EPS $-5.75 vs $-4.59 estimate

Missed consensus by 95.4% — EPS $-2.99 vs $-1.53 estimate

Missed consensus by 30.7% — EPS $-6.5 vs $-4.9725 estimate

Missed consensus by 65.4% — EPS $-6.75 vs $-4.08 estimate

Beat consensus by 8.4% — EPS $0.96 vs $0.8856 estimate

Beat consensus by 9.3% — EPS $1.01 vs $0.9238 estimate

Beat consensus by 8.2% — EPS $0.89 vs $0.8222 estimate

Beat consensus by 21.4% — EPS $0.26 vs $0.2142 estimate

Beat consensus by 12.0% — EPS $0.24 vs $0.2142 estimate

Missed consensus by 15.2% — EPS $0.16 vs $0.1887 estimate

Beat consensus by 50.5% — EPS $0.22 vs $0.1462 estimate

Missed consensus by 14.8% — EPS $-1.17 vs $-1.0196 estimate

Missed consensus by 20.8% — EPS $-0.93 vs $-0.7701 estimate

Missed consensus by 29.3% — EPS $-0.51 vs $-0.3944 estimate

Beat consensus by 55.4% — EPS $-0.15 vs $-0.3363 estimate

Missed consensus by 9.2% — EPS $0.68 vs $0.7486 estimate

Beat consensus by 10.2% — EPS $1.95 vs $1.7692 estimate

Beat consensus by 11.7% — EPS $1.07 vs $0.9581 estimate

Beat consensus by 17.1% — EPS $1.97 vs $1.6817 estimate

Beat consensus by 13.1% — EPS $1.27 vs $1.1228 estimate

Missed consensus by 191.3% — EPS $-0.06 vs $-0.0206 estimate

Missed consensus by 191.3% — EPS $-0.03 vs $-0.0103 estimate

Beat consensus by 51.5% — EPS $-0.01 vs $-0.0206 estimate

Beat consensus by 19.6% — EPS $0.58 vs $0.4848 estimate

Missed consensus by 7.6% — EPS $0.56 vs $0.606 estimate

Missed consensus by 11.7% — EPS $0.58 vs $0.6565 estimate

Beat consensus by 25.4% — EPS $0.34 vs $0.2712 estimate

Missed consensus by 37.4% — EPS $0.21 vs $0.3356 estimate

Missed consensus by 110.9% — EPS $-0.03 vs $0.2749 estimate

Missed consensus by 9.7% — EPS $0.33 vs $0.3655 estimate

Beat consensus by 25.3% — EPS $0.72 vs $0.5746 estimate

Missed consensus by 6.3% — EPS $0.45 vs $0.4801 estimate

Beat consensus by 12.3% — EPS $1.1 vs $0.9797 estimate

Beat consensus by 11.7% — EPS $0.97 vs $0.8686 estimate

Beat consensus by 6.8% — EPS $1.37 vs $1.2827 estimate

Missed consensus by 36.8% — EPS $-1.3 vs $-0.9506 estimate

Beat consensus by 28.7% — EPS $0.21 vs $0.1632 estimate

Missed consensus by 42.1% — EPS $0.07 vs $0.1209 estimate

Missed consensus by 8.8% — EPS $0.4 vs $0.4386 estimate

Missed consensus by 6.4% — EPS $0.42 vs $0.4488 estimate

Missed consensus by 11.7% — EPS $0.41 vs $0.4641 estimate

Missed consensus by 214.0% — EPS $-0.29 vs $0.2544 estimate

Missed consensus by 191.8% — EPS $-0.09 vs $0.098 estimate

Missed consensus by 264.8% — EPS $-0.77 vs $-0.2111 estimate

Beat consensus by 79.9% — EPS $-0.29 vs $-1.441 estimate

Beat consensus by 100.0% — EPS $0 vs $-0.0103 estimate

Missed consensus by 55.3% — EPS $1.54 vs $3.4476 estimate

Missed consensus by 29.4% — EPS $2.29 vs $3.2436 estimate

Beat consensus by 35.4% — EPS $4.17 vs $3.0804 estimate

Beat consensus by 8.0% — EPS $3.68 vs $3.4068 estimate

Beat consensus by 7.5% — EPS $0.91 vs $0.8466 estimate

Beat consensus by 83.2% — EPS $1.57 vs $0.8568 estimate

Beat consensus by 105.7% — EPS $1.5 vs $0.7293 estimate

Beat consensus by 42.9% — EPS $1.21 vs $0.8466 estimate

Beat consensus by 16.6% — EPS $-0.71 vs $-0.8517 estimate

Missed consensus by 30.1% — EPS $-0.71 vs $-0.5457 estimate

Missed consensus by 37.9% — EPS $-0.75 vs $-0.544 estimate

Missed consensus by 14.9% — EPS $-20.4 vs $-17.748 estimate

Beat consensus by 77.3% — EPS $-2.06 vs $-9.0576 estimate

Beat consensus by 58.9% — EPS $-20.04 vs $-48.7152 estimate

Missed consensus by 32.7% — EPS $-1.99 vs $-1.4994 estimate

Missed consensus by 11.9% — EPS $0.54 vs $0.6127 estimate

Beat consensus by 20.9% — EPS $0.59 vs $0.4882 estimate

Beat consensus by 137.0% — EPS $0.75 vs $0.3165 estimate

Missed consensus by 36.8% — EPS $0.3 vs $0.4747 estimate

Beat consensus by 14.2% — EPS $0.77 vs $0.6745 estimate

Beat consensus by 10.2% — EPS $0.78 vs $0.708 estimate

Beat consensus by 236.9% — EPS $0.19 vs $0.0564 estimate

Beat consensus by 38.5% — EPS $0.55 vs $0.397 estimate

Beat consensus by 30.1% — EPS $2.28 vs $1.7529 estimate

Beat consensus by 25.2% — EPS $1.81 vs $1.4454 estimate

Beat consensus by 13.2% — EPS $1.68 vs $1.4846 estimate

Missed consensus by 46.1% — EPS $0.68 vs $1.2611 estimate

Missed consensus by 10.2% — EPS $2.97 vs $3.3074 estimate

Missed consensus by 23.0% — EPS $0.49 vs $0.6363 estimate

Missed consensus by 11.6% — EPS $0.53 vs $0.5993 estimate

Missed consensus by 5.2% — EPS $0.6 vs $0.6329 estimate

Missed consensus by 33.8% — EPS $-43 vs $-32.13 estimate

Missed consensus by 139.3% — EPS $-277 vs $-115.77 estimate

Beat consensus by 22.8% — EPS $-37 vs $-47.94 estimate

Missed consensus by 152.8% — EPS $-1045.55 vs $-413.61 estimate

Beat consensus by 13.2% — EPS $1 vs $0.8835 estimate

Beat consensus by 15.1% — EPS $1.09 vs $0.9474 estimate

Beat consensus by 12.3% — EPS $1.18 vs $1.0508 estimate

Beat consensus by 17.2% — EPS $1 vs $0.8532 estimate

Missed consensus by 5.1% — EPS $2.69 vs $2.8356 estimate

Missed consensus by 8.1% — EPS $3.02 vs $3.2844 estimate

Missed consensus by 9.2% — EPS $2.5 vs $2.754 estimate

Missed consensus by 34.6% — EPS $0.6 vs $0.918 estimate

Beat consensus by 12.1% — EPS $-0.32 vs $-0.3641 estimate

Missed consensus by 482.4% — EPS $-0.26 vs $0.068 estimate

Missed consensus by 116.4% — EPS $-0.34 vs $-0.1571 estimate

Missed consensus by 251.0% — EPS $-0.76 vs $0.5032 estimate

Missed consensus by 23.8% — EPS $1.34 vs $1.7574 estimate

Missed consensus by 30.6% — EPS $1.1 vs $1.5844 estimate

Missed consensus by 239.7% — EPS $-0.56 vs $0.401 estimate

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

Gold +3.05% — significant rally

OSINT: Iranian ballistic missile intercepted west of Jerusalem

CFTC CRUDE OIL WTI speculator at extreme short — contrarian bull signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

Gold +3.66% — significant rally

Oil -3.90% — significant selloff